Efficacy and Safety of Bevacizumab-based Maintenance Therapy in Metastatic Colorectal Cancer: A Meta-analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2019 Dec 20

PMID 31852082

Citations 10

Authors

Hongbo Ma

Xiaoli Wu

Miaomiao Tao

Nan Tang

Yanyan Li

Xianquan Zhang

Qi Zhou

Affiliations

Soon will be listed here.

Abstract

Objective: To identify the optimal treatment strategy after first-line induction chemotherapy for metastatic colorectal cancer (mCRC).

Methods: We conducted a meta-analysis of randomized controlled trials comparing bevacizumab-based maintenance therapy, observation, and continuous chemotherapy.We searched the PubMed, Embase, and Cochrane databases for relevant articles published through March 2018. All randomized phase-III trials evaluating bevacizumab-based maintenance treatment after bevacizumab-based induction treatment were eligible for inclusion. The primary and secondary endpoints were progression-free survival (PFS) and overall survival (OS), respectively. Hazard ratios (HRs) with 95% confidence intervals (CIs) or data for calculating HRs with 95% CIs were extracted. The RevMan v5.3 (Copenhagen, Denmark) software was used for data analysis.

Results: Nine trials (3121 patients) were included in this meta-analysis. Compared with observation alone, bevacizumab-based maintenance therapy significantly improved PFS (HR: 0.62, 95% CI: 0.47-0.82) and showed a trend toward prolonged OS (HR: 0.93, 95% CI: 0.83-1.05). The incidence of grade 3/4 toxicity, including hypertension and fatigue, was higher after maintenance therapy than after observation alone. PFS (HR: 0.91, 95% CI: 0.70-1.18) and OS (HR: 0.88, 95% CI: 0.74-1.04) did not differ between the maintenance treatment and continuous chemotherapy groups. Grade 3/4 toxicity, including diarrhea and sensory neuropathy, was less common after maintenance therapy than after continuous chemotherapy.

Conclusion: Bevacizumab-based maintenance therapy significantly improved PFS, showed a trend toward prolonged OS, and reduced cumulative grade 3/4 toxicity relative to continuous chemotherapy with comparable efficacy. Although maintenance therapy was beneficial, the optimal strategy should be individualized.

Citing Articles

Metastatic Colon Cancer - An Effective Treatment Protocol of Integrative Therapies Including Electromagnetic Field Frequencies: A Case Report.

Ried K, Eng P, Binjemain T Case Rep Oncol. 2023; 16(1):1324-1334.

PMID: 37942404 PMC: 10629860. DOI: 10.1159/000534628.

A Real-World Retrospective Study to Evaluate the Reliability of Cetuximab plus Capecitabine versus Capecitabine as Maintenance Therapy in Patients with RAS and BRAF Wild-Type Metastatic Colorectal Cancer.

Li J, Zhang H, Guo X, Dong S, Li Y, Huang W Med Princ Pract. 2023; 33(1):31-40.

PMID: 37725905 PMC: 10896611. DOI: 10.1159/000533528.

Risk of retinal vein occlusion in colorectal cancer patients receiving anti-vascular endothelial growth factors - a population-based cohort study.

Annabelle Lee W, Chung W, Shao S, Lai E, Chen Y, Ho C BMC Cancer. 2023; 23(1):545.

PMID: 37316803 PMC: 10265868. DOI: 10.1186/s12885-023-11037-4.

Real-Life Effectivity of Dose Intensity Reduction of First-Line mFOLFIRI-Based Treatment of Metastatic Colorectal Cancers: Sometimes Less Is More.

Pecsi B, Mangel L Curr Oncol. 2023; 30(1):908-922.

PMID: 36661718 PMC: 9857654. DOI: 10.3390/curroncol30010069.

Antiangiogenic Drug-Induced Proteinuria as a Prognostic Factor in Metastatic Colorectal Cancer.

Moisuc D, Marinca M, Gafton B, Alexa-Stratulat T, Pavel-Tanasa M, Cianga P Curr Oncol. 2022; 29(6):3996-4011.

PMID: 35735428 PMC: 9221669. DOI: 10.3390/curroncol29060319.

References

Fakih M . Metastatic colorectal cancer: current state and future directions. J Clin Oncol. 2015; 33(16):1809-24. DOI: 10.1200/JCO.2014.59.7633. View

Simkens L, van Tinteren H, May A, Ten Tije A, Creemers G, Loosveld O . Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015; 385(9980):1843-52. DOI: 10.1016/S0140-6736(14)62004-3. View

Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, Andre T, Bennamoun M . Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol. 2009; 27(34):5727-33. DOI: 10.1200/JCO.2009.23.4344. View

Johnsson A, Hagman H, Frodin J, Berglund A, Keldsen N, Fernebro E . A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial. Ann Oncol. 2013; 24(9):2335-41. DOI: 10.1093/annonc/mdt236. View

Aparicio T, Ghiringhelli F, Boige V, Le Malicot K, Taieb J, Bouche O . Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). J Clin Oncol. 2018; 36(7):674-681. DOI: 10.1200/JCO.2017.75.2931. View

Franken M, van Rooijen E, May A, Koffijberg H, van Tinteren H, Mol L . Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer. Eur J Cancer. 2017; 75:204-212. DOI: 10.1016/j.ejca.2017.01.019. View

Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N . Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol. 2005; 23(22):4866-75. DOI: 10.1200/JCO.2005.07.113. View

Koeberle D, Betticher D, von Moos R, Dietrich D, Brauchli P, Baertschi D . Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Ann Oncol. 2015; 26(4):709-714. DOI: 10.1093/annonc/mdv011. View

Diaz-Rubio E, Gomez-Espana A, Massuti B, Sastre J, Abad A, Valladares M . First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist. 2012; 17(1):15-25. PMC: 3267817. DOI: 10.1634/theoncologist.2011-0249. View

10.

Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M . Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001; 19(21):4097-106. DOI: 10.1200/JCO.2001.19.21.4097. View

11.

Siegel R, Ma J, Zou Z, Jemal A . Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1):9-29. DOI: 10.3322/caac.21208. View

12.

Siegel R, DeSantis C, Jemal A . Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014; 64(2):104-17. DOI: 10.3322/caac.21220. View

13.

de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J . Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18(16):2938-47. DOI: 10.1200/JCO.2000.18.16.2938. View

14.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

15.

Douillard J, Cunningham D, Roth A, Navarro M, James R, Karasek P . Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000; 355(9209):1041-7. DOI: 10.1016/s0140-6736(00)02034-1. View

16.

Yalcin S, Uslu R, Dane F, Yilmaz U, Zengin N, Buyukunal E . Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial. Oncology. 2013; 85(6):328-35. DOI: 10.1159/000355914. View

17.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

18.

Presta L, Chen H, OConnor S, Chisholm V, Meng Y, Krummen L . Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997; 57(20):4593-9. View

19.

Tournigand C, Chibaudel B, Samson B, Scheithauer W, Vernerey D, Mesange P . Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2015; 16(15):1493-1505. DOI: 10.1016/S1470-2045(15)00216-8. View

20.

Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M . Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer. 2012; 48(10):1466-75. DOI: 10.1016/j.ejca.2012.02.057. View